RVMDRevolution Medicines, Inc.Signing up patients
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Adenocarcinoma Metastatic · Pancreatic Adenocarcinoma · Pancreatic Adenosquamous Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 900 (planned)
- Started
- Mar 9, 2026
- Main results expected
- Jun 2028
- Fully finished
- Mar 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS)
Measured over: Up to approximately 2 years
Overall survival (OS)
Measured over: Up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07491445 · record last updated 2026-10-02 · checked 2026-11-09 15:47 UTC